For the Inventor, By the Inventor

Enter assignee name

Electronic, India

Biocon Limited

USPTO Granted Patents = 112

% Expired Patents = 24.1

CIPO Patents = 12

EPO Patents = 55

Trademarks = 1

Forward Citations = 341

Loading Chart...

Loading Chart...

212 inventors (with patents filed for the assignee):

Nnochiri Ekwuribe (29 out of 72 patents)

Ramakrishnan Melarkode (19 out of 21 patents)

Kedarnath Nanjund Sastry (18 out of 19 patents)

4. Balasingam Radhakrishnan (16 out of 38 patents)

5. Nagaraj Govindappa (15 out of 16 patents)

6. Laxmi Adhikary (11 out of 12 patents)

7. Sambasivam Ganesh (11 out of 13 patents)

8. Pradip Nair (10 out of 11 patents)

9. Maria Melina Soares (10 out of 11 patents)

10. Sanjay Tiwari (10 out of 26 patents)

11. Harish Iyer (10 out of 17 patents)

12. Jose Enrique Montero Casimiro (9 out of 12 patents)

13. Shrikumar Suryanarayan (9 out of 18 patents)

14. Kenneth D James (9 out of 10 patents)

15. Mark A Miller (8 out of 173 patents)

Core Competencies:

GLP-1 Analogues

Insulin Crystallization

Fusion Proteins

Monoclonal Antibodies

Immunomodulatory

Glycoprotein De-glycosylation

Polymorphic Forms

EGFR Targeting

Protein Formulations

Nucleotide Sequences

Fucosylation Control

Cancer Treatment

112 patents: Sort by Forward Citations

1. 12570689 - Purification of GLP-1 analogues (2026-03-10),

2. 12509488 - Preparative crystallization of recombinant human insulin (2025-12-30),

3. 12351636 - Fusion immunomodulatory proteins and methods for making same (2025-07-08),

4. 12098136 - Crystalline forms of lenalidomide (2024-09-24),

5. 12049632 - Anti-EGFR1-PD1 targeted/immunomodulatory fusion protein (2024-07-30),

6. 11981743 - Monoclonal antibody and a method thereof (2024-05-14),

7. 11629120 - Trisodium sacubitril valsartan and process for its preparation (2023-04-18),

8. 11530403 - Rapid and efficient de-glycosylation of glycoproteins (2022-12-20),

9. 11442067 - Peptide mapping method for sequence identification of insulin and insulin analogues (2022-09-13),

10. 11340238 - Method for detecting neutralizing antibodies against recombinant human insulin in human serum (2022-05-24),

11. 11242401 - Monoclonal antibody and a method of use for the treatment of lupus (2022-02-08),

12. 11231384 - Humidity sensor (2022-01-25),

13. 11203585 - Crystalline forms of lenalidomide (2021-12-21),

14. 11066439 - Synthesis of liraglutide (2021-07-20),

15. 11060097 - Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins (2021-07-13),

Company Overview

Biocon Limited, headquartered in Electronic City, India, is a leading biopharmaceutical company specializing in the development and manufacturing of innovative therapies. The company focuses on immunotherapy proteins, with expertise in GLP-1 analogues, insulin crystallization, and monoclonal antibodies. Biocon's research encompasses advanced technologies such as fusion proteins and immunomodulatory agents, targeting critical areas like EGFR. The organization is committed to enhancing patient outcomes through its cutting-edge biopharmaceutical solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

112 Patents

#1 in Electronic

#21 in India

#7,057 in the World

Electronic, India

Biocon Limited

Forward Citations = 341

212 inventors:

Nnochiri Ekwuribe (29 out of 72 patents)

Ramakrishnan Melarkode (19 out of 21 patents)

Kedarnath Nanjund Sastry (18 out of 19 patents)

4. Balasingam Radhakrishnan (16 out of 38 patents)

5. Nagaraj Govindappa (15 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Biocon Limited. Retrieved from https://idiyas.com/company/biocon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…